Trospium

Generic Name: Trospium

Brand Names: Trosec

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₀NO_₃

CAS Number: 47608-32-2

Unique Ingredient Identifier: T4Y8ORK057

Background: Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by Indevus Pharmaceutical Inc. and was granted FDA approval in 2007.

Indication: For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.

Associated Conditions: Overactive Bladder Syndrome (OABS)

Associated Therapies: -

Clinical Trials

Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls

Early Phase 1

Recruiting

Conditions: Accidental Falls
Urinary Bladder, Overactive
Urinary Incontinence

Interventions: Behavioral: Pelvic Floor Muscle Training
Drug: Mirabegron
Drug: Trospium Chloride

First Posted Date: 2023-05-30

Last Posted Date: 2024-12-20

Lead Sponsor: The University of Texas Medical Branch, Galveston

Target Recruit Count: 48

Registration Number: NCT05880862

Locations: 🇺🇸
University of Texas Medical Branch at Galveston, Galveston, Texas, United States

Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence

Phase 4

Recruiting

Conditions: Urgency Urinary Incontinence

Interventions: Drug: Trospium
Drug: Placebo oral tablet

First Posted Date: 2020-01-13

Last Posted Date: 2024-12-11

Lead Sponsor: Becky Clarkson

Target Recruit Count: 220

Registration Number: NCT04227184

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms:

Not Applicable

Suspended

Conditions: Ureter Stone
Quality of Life
Ureter Obstruction

Interventions: Drug: Trospium Chloride
Drug: Tamsulosin

First Posted Date: 2018-10-17

Last Posted Date: 2023-10-12

Lead Sponsor: Mansoura University

Target Recruit Count: 200

Registration Number: NCT03709992

Locations: 🇪🇬
Ahmed R EL-Nahas, Mansoura, Kuwait, Egypt

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Completed

Conditions: Overactive Bladder (OAB)

Interventions: Drug: mirabegron
Drug: solifenacin
Drug: darifenacin
Drug: imidafenacin
Drug: tolterodine
Drug: oxybutynin
Drug: trospium
Drug: fesoterodine
Drug: propiverine

First Posted Date: 2018-07-27

Last Posted Date: 2024-10-16

Lead Sponsor: Astellas Pharma Singapore Pte. Ltd.

Target Recruit Count: 5589

Registration Number: NCT03602508

Locations: 🇦🇺
Site AU10000, Sydney, Australia
🇰🇷
Site KR82001, Seoul, Korea, Republic of

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Completed

Conditions: Overactive Bladder (OAB)

Interventions: Device: solifenacin
Drug: mirabegron
Drug: darifenacin
Drug: imidafenacin
Drug: tolterodine
Drug: oxybutynin
Drug: trospium
Drug: fesoterodine
Device: propiverine

First Posted Date: 2018-06-28

Last Posted Date: 2020-04-22

Lead Sponsor: Astellas Pharma Singapore Pte. Ltd.

Target Recruit Count: 805

Registration Number: NCT03572231

Locations: 🇰🇷
Site KR410008, Daejeon, Korea, Republic of
🇰🇷
Site KR410009, Incheon, Korea, Republic of
🇰🇷
Site KR410005, Kangam, Korea, Republic of

and more 12 locations

Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: xanomeline tartrate
Drug: Trospium chloride

First Posted Date: 2016-07-13

Last Posted Date: 2017-04-19

Lead Sponsor: Karuna Therapeutics

Target Recruit Count: 70

Registration Number: NCT02831231

Locations: 🇺🇸
Medpace, Cincinnati, Ohio, United States

The Effect of Anticholinergics on Cognitive Function in the Elderly

Phase 4

Completed

Conditions: Cognitive Function
Mental Competency
Urinary Bladder, Overactive

Interventions: Drug: Trospium Chloride
Drug: Placebo

First Posted Date: 2013-08-14

Last Posted Date: 2017-03-22

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 59

Registration Number: NCT01922115

Locations: 🇺🇸
Unc Chapel Hill Urogynecology A2 Clinic, Chapel Hill, North Carolina, United States

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

Phase 4

Completed

Conditions: Overactive Bladder

Interventions: Drug: trospium chloride
Drug: oxybutynin IR
Drug: oxybutynin IR placebo

First Posted Date: 2010-08-10

Last Posted Date: 2016-02-26

Lead Sponsor: Allergan

Target Recruit Count: 20

Registration Number: NCT01178827

Anticholinergic vs. Botox Comparison Study

Phase 3

Completed

Conditions: Urge Urinary Incontinence
Overactive Bladder

Interventions: Drug: Solifenacin 5mg
Drug: Botulinum toxin A (Botox A®)
Drug: Solifenacin 10mg
Drug: Trospium chloride

First Posted Date: 2010-07-21

Last Posted Date: 2018-05-02

Lead Sponsor: NICHD Pelvic Floor Disorders Network

Target Recruit Count: 249

Registration Number: NCT01166438

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Magee-Women's Hospital, Pittsburgh, Pennsylvania, United States

and more 8 locations

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

Phase 4

Completed

Conditions: Overactive Bladder

Interventions: Drug: trospium chloride
Drug: placebo

First Posted Date: 2010-03-19

Last Posted Date: 2013-09-26

Lead Sponsor: Allergan

Target Recruit Count: 322

Registration Number: NCT01089751

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy